Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema

Current Medical Research and Opinion

Volumn 33, Issue , 2017, Pages 5-17

  Holden, Sarah E ^a   Currie, Craig J ^a,b   Owens, David R ^c  

^a Pharmatelligence   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

diabetic macular edema; Fluocinolone acetonide; intraocular pressure; retrospective; visual acuity

Indexed keywords

FLUOCINOLONE ACETONIDE; GLUCOCORTICOID;

AGED; ARTICLE; CATARACT EXTRACTION; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DIABETIC MACULAR EDEMA; DISEASE DURATION; DRUG IMPLANT; FEMALE; FLUOCINOLONE ACETONIDE IMPLANT; HUMAN; INTRAOCULAR PRESSURE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; STEROID THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; CLINICAL TRIAL; DIABETIC RETINOPATHY; MACULAR EDEMA; MIDDLE AGED; MULTICENTER STUDY;

AGED; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 85029444065     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2017.1366645     Document Type: Article

References (24)

1. Medicines and Healthcare Products Regulatory Agency. Public assessment report mutual recognition procedure ILUVIEN® 190 micrograms intravitreal implant in applicator (fluocinolone acetonide). 2015. Available at: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con171936.pdf. [Last accessed December 6, 2016]
2. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-32
3. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35
4. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806
5. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016;123:1351-9
6. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-22
7. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt vs. deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015;122:375-81
8. The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-203
9. European Medicines Agency. Questions and answers following the initial experience of the Adaptive Licensing Pilot project; 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/09/WC500172810.pdf. [Last accessed February 21, 2017]
10. Rakic J-M, Leys A, Brié H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 2013;7:1849-58
11. Souied EH, Oubraham H, Mimoun G, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice. Retina 2015;35:1743-9
12. Figueira J, Henriques J, Amaro M, et al. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res 2017;57:166-72
13. Schmit-Eilenberger VK., A novel intravitreal fluocinolone acetonide implant (Iluvien(R)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol 2015;9:801-11
14. Elaraoud I, Andreatta W, Kidess A, et al. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol 2016;16:3
15. ®) in patients with diabetic macular edema. Ophthalmol Ther 2016;5:95-104
16. Massin P, Erginay A, Dupas B, et al. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol 2016;10:1257-64
17. El-Ghrably I, Steel DHW, Habib M, et al. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience. Eur J Ophthalmol 2017;27:357-62
18. Gregori NZ, Feuer W, Rosenfeld PJ., Novel method for analyzing snellen visual acuity measurements. Retina 2010;30:1046-50
19. Haukoos JS, Newgard CD., Advanced statistics: missing data in clinical research—part 1: an introduction and conceptual Framework. Acad Emerg Med 2007;14:662-8
20. National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy; 2013. Available at: www.nice.org.uk/guidance/ta301. [Last accessed October 24, 2014]
21. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014;121:1892-903
22. Bailey C, Chakravarthy U, Lotery A, et al. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye 2017 (epub ahead of print)
23. Parrish RK, Campochiaro PA, Pearson PA, et al. Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the fame trials. Ophthalmic Surg Lasers Imaging Retin 2016;47:426-35
24. Parrish RK, Traverso CE, Green K, et al. Quantitative assessment of optic nerve changes in patients with diabetic macular edema treated with fluocinolone acetonide vitreous implants. Ophthalmic Surg Lasers Imaging Retin 2016;47:418-25